This course has expired. View available courses.
Neurology, Musculoskeletal Health
Targeting Unmet Needs in the Treatment of Focal Spasticity: CME
The management of spasticity can be complex. The common treatment for focal spasticity is botulinum toxin-A (BoNT-A) therapy. As the effects of BoNT-A wear off, the recurrence of symptoms can be distressing to patients and may have a significant impact on quality of life. This program describes how patients can be affected and outlines multi-modal approaches to the management of disruptive symptoms in order to improve patient outcomes.
This program has received an educational grant or in-kind support from Ipsen Biopharmaceuticals Canada Inc.
DURATION
30 min
PROFESSION
Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2023-03-25
The management of spasticity can be complex. The common treatment for focal spasticity is botulinum toxin-A (BoNT-A) therapy. As the effects of BoNT-A wear off, the recurrence of symptoms can be distressing to patients and may have a significant impact on quality of life. This program describes how patients can be affected and outlines multi-modal approaches to the management of disruptive symptoms in order to improve patient outcomes.
This program has received an educational grant or in-kind support from Ipsen Biopharmaceuticals Canada Inc.
Faculty
Heather Finlayson, MD, FRCPC, Dip. Sport Med, CSCN (EMG)
Colleen O’Connell, MD, FRCPC
Omar D. Khan, MD, FRCPC
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Describe the frequency and impact of symptom recurrence between botulinum toxin-A (BoNT-A) injections
- Discuss multi-modal treatment considerations in persons experiencing problematic spasticity while treated with BoNT-A
- Select appropriate treatment options for patients who experience disruptive symptoms towards the end of their treatment cycle